In summary, the NLRP3 inflammasome is a key element that induces and exacerbates AD and tau pathologies, suggesting that targeting NLRP3 with therapeutic strategies has the potential to slow the progression of AD and improve cognitive function. The gene discussed is NLRP3; the disease is Alzheimer disease.